Essentra plc (FRA:HOF)
Germany · Delayed Price · Currency is EUR 1.210
+0.010 (0.83%)
Last updated: Jul 31, 2025
Intra-Cellular Therapies Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 295.1 | 302.4 | 316.3 | 337.9 | 301.7 | 896.5 | Upgrade | |
Revenue Growth (YoY) | -4.71% | -4.40% | -6.39% | 12.00% | -66.35% | -7.97% | Upgrade |
Cost of Revenue | 165.6 | 165.3 | 174.5 | 189.7 | 275.3 | 834.2 | Upgrade |
Gross Profit | 129.5 | 137.1 | 141.8 | 148.2 | 26.4 | 62.3 | Upgrade |
Selling, General & Admin | 0.5 | 0.5 | 0.4 | - | 0.4 | 0.7 | Upgrade |
Other Operating Expenses | 106.2 | 111 | 121.7 | 137.1 | -1.5 | 8.9 | Upgrade |
Operating Expenses | 118.2 | 123 | 133.4 | 147.5 | 7.5 | 32.2 | Upgrade |
Operating Income | 11.3 | 14.1 | 8.4 | 0.7 | 18.9 | 30.1 | Upgrade |
Interest Expense | -13.5 | -9.2 | -7.8 | -22.1 | -13.4 | -14.2 | Upgrade |
Interest & Investment Income | 4.9 | 0.5 | 3.5 | 1.4 | - | 0.8 | Upgrade |
Currency Exchange Gain (Loss) | -1.8 | -1.8 | 3.1 | 1.5 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 0.5 | 0.5 | -2.3 | -1.8 | -1 | -1.6 | Upgrade |
EBT Excluding Unusual Items | 1.4 | 4.1 | 4.9 | -20.3 | 4.5 | 15.1 | Upgrade |
Merger & Restructuring Charges | - | - | - | -11.5 | -3.6 | -14.5 | Upgrade |
Asset Writedown | - | - | - | -0.5 | - | - | Upgrade |
Other Unusual Items | 1.6 | 1.6 | 3.5 | 3.2 | -8 | -4.7 | Upgrade |
Pretax Income | 3 | 5.7 | 8.4 | -29.1 | -7.1 | -4.1 | Upgrade |
Income Tax Expense | -6.4 | -5.9 | 2.6 | 2 | -2.2 | -2.6 | Upgrade |
Earnings From Continuing Operations | 9.4 | 11.6 | 5.8 | -31.1 | -4.9 | -1.5 | Upgrade |
Earnings From Discontinued Operations | 0.2 | -1 | -0.4 | -152.7 | 33.2 | - | Upgrade |
Net Income to Company | 9.6 | 10.6 | 5.4 | -183.8 | 28.3 | -1.5 | Upgrade |
Minority Interest in Earnings | - | - | - | -4.2 | -1.4 | -1.8 | Upgrade |
Net Income | 9.6 | 10.6 | 5.4 | -188 | 26.9 | -3.3 | Upgrade |
Net Income to Common | 9.6 | 10.6 | 5.4 | -188 | 26.9 | -3.3 | Upgrade |
Net Income Growth | - | 96.30% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 287 | 287 | 295 | 301 | 301 | 273 | Upgrade |
Shares Outstanding (Diluted) | 289 | 290 | 297 | 301 | 302 | 275 | Upgrade |
Shares Change (YoY) | -0.05% | -2.46% | -1.36% | -0.40% | 10.05% | 3.43% | Upgrade |
EPS (Basic) | 0.03 | 0.04 | 0.02 | -0.62 | 0.09 | -0.01 | Upgrade |
EPS (Diluted) | 0.03 | 0.04 | 0.02 | -0.62 | 0.09 | -0.01 | Upgrade |
EPS Growth | - | 99.40% | - | - | - | - | Upgrade |
Free Cash Flow | 11.1 | 13.8 | 17.1 | 24.3 | 24.7 | 61.9 | Upgrade |
Free Cash Flow Per Share | 0.04 | 0.05 | 0.06 | 0.08 | 0.08 | 0.23 | Upgrade |
Dividend Per Share | 0.024 | 0.028 | 0.036 | 0.033 | 0.060 | 0.033 | Upgrade |
Dividend Growth | -35.62% | -22.22% | 9.09% | -45.00% | 81.82% | -47.62% | Upgrade |
Gross Margin | 43.88% | 45.34% | 44.83% | 43.86% | 8.75% | 6.95% | Upgrade |
Operating Margin | 3.83% | 4.66% | 2.66% | 0.21% | 6.26% | 3.36% | Upgrade |
Profit Margin | 3.25% | 3.50% | 1.71% | -55.64% | 8.92% | -0.37% | Upgrade |
Free Cash Flow Margin | 3.76% | 4.56% | 5.41% | 7.19% | 8.19% | 6.91% | Upgrade |
EBITDA | 33.8 | 37.2 | 33.7 | 27.7 | 42.4 | 92.5 | Upgrade |
EBITDA Margin | 11.45% | 12.30% | 10.65% | 8.20% | 14.05% | 10.32% | Upgrade |
D&A For EBITDA | 22.5 | 23.1 | 25.3 | 27 | 23.5 | 62.4 | Upgrade |
EBIT | 11.3 | 14.1 | 8.4 | 0.7 | 18.9 | 30.1 | Upgrade |
EBIT Margin | 3.83% | 4.66% | 2.66% | 0.21% | 6.26% | 3.36% | Upgrade |
Effective Tax Rate | - | - | 30.95% | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.